Synopsis
Highlights
History
Business
Property
Subsidiaries
Long term debt
Capital stock
Earnings estimates
Business segments
Download
Printer Friendly
|
|||||||||||||||||||||||||||||
Business Summary
Allergan is a pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Co. has three segments: United States Specialized Therapeutics, which includes products within the United States, including Medical Aesthetics, Medical Dermatology Eye Care and Neuroscience and Urology therapeutic products; United States General Medicine, which includes products within the United States that do not fall into the United States Specialized Therapeutics business units, including Central Nervous System; and International, which includes products sold outside the United States.Pricing Summary
Time Period
No Chart Available
| Yesterday | 5 Days | 30 Days | |
|---|---|---|---|
| Close | 193.02 | 193.02 | 193.02 |
| Volume | N/A | N/A | N/A |
| 52 Week High/Low : | 202.10 - 115.73 | ||
| % Price Change (100 Days) : | N/A | ||
| 200-Day Moving Avg. : | 186.09 | ||
Company News
There is no news found for this company
Corporate Events
Key Executives
| Age | ||
|---|---|---|
| President | 51 | |
| Director | ||
| Director | ||
| Director | ||
| Director | ||
Key Financials
(In USD as of 03/31/2020)| Income Statement | |
|---|---|
| Revenue | 16,096m |
| Net Income | -2,485m |
| EPS from Continuing Operations | -7.61 |
| EPS - Net Income - Diluted | -7.61 |
| Revenue per Share | 48.91 |
| Balance Sheet | |
| Total Assets | 88,426m |
| Total Liabilities | 30,429m |
| Shareholders' Equity | 57,998m |
| Total Assets per Share | 268.20 |
| Net Assets per Share | 175.91 |
| Cash Flows | |
| Cash from Operations | 6,121m |
| Cash from Investing | -1,075m |
| Cash from Financing | -4,808m |
| Capital Expenditures | 371m |
| Cash Flow per Share | 18.44 |